LIST OF TABLES

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 1.1</td>
<td>Summary of the antiretroviral drugs along with their physicochemical and pharmacokinetic properties</td>
<td>7</td>
</tr>
<tr>
<td>Table 1.2</td>
<td>Key instances of commonly employed lipids, emulsifiers and cosolvents in the formulation of SNEOFs</td>
<td>17</td>
</tr>
<tr>
<td>Table 1.3</td>
<td>Various studies employed for characterization of the SNEOFs</td>
<td>20</td>
</tr>
<tr>
<td>Table 1.4</td>
<td>Recent instances of marketed products on the lipid-based self-emulsifying formulations</td>
<td>22</td>
</tr>
<tr>
<td>Table 1.5</td>
<td>Recent literature reports on bioavailability enhancement of drugs</td>
<td>23</td>
</tr>
<tr>
<td>Table 1.6</td>
<td>Recent literature instances of a variety of drugs loaded into liquid self-nanoemulsifying oily formulations</td>
<td>25</td>
</tr>
<tr>
<td>Table 1.7</td>
<td>Recent literature instances on various types of solid SEDDS</td>
<td>26</td>
</tr>
<tr>
<td>Table 1.8</td>
<td>Recent instances of nanocarriers employed to enhance the oral bioavailability of antiretroviral drugs</td>
<td>35</td>
</tr>
<tr>
<td>Table 1.9</td>
<td>Recent instances of nanocarriers employed to enhance the biodistribution of the antiretroviral drugs via oral and non-oral route</td>
<td>36</td>
</tr>
<tr>
<td>Table 1.10</td>
<td>Various studies employed for characterization of the SLNs/NLCs</td>
<td>38</td>
</tr>
<tr>
<td>Table 1.11</td>
<td>IVIVC in the light of BCS</td>
<td>43</td>
</tr>
<tr>
<td>Table 1.12</td>
<td>Comparison of OVAT and DoE methodology</td>
<td>45</td>
</tr>
<tr>
<td>Table 1.13</td>
<td>Experimental designs usually employed during QbD-based pharmaceutical product development</td>
<td>55</td>
</tr>
<tr>
<td>Table 1.14</td>
<td>Suitability of various optimization methods under variegated situations</td>
<td>58</td>
</tr>
<tr>
<td>Table 1.15</td>
<td>Recent instances on QbD-oriented development of lipid-based drug delivery systems</td>
<td>58</td>
</tr>
<tr>
<td>Table 3.1</td>
<td>Materials, chemicals and reagents used in the current research work</td>
<td>73</td>
</tr>
<tr>
<td>Table 3.2</td>
<td>List of equipment/software employed during the current studies</td>
<td>75</td>
</tr>
<tr>
<td>Table 3.3</td>
<td>Quality target product profile for self-nanoemulsifying oily formulations of lopinavir</td>
<td>81</td>
</tr>
<tr>
<td>Table 3.4</td>
<td>Critical quality attributes for self-nanoemulsifying oily formulation of lopinavir and their justifications</td>
<td>81</td>
</tr>
<tr>
<td>Table 3.5</td>
<td>CMAs and CPPs with their respective low and high levels screened for lopinavir SNEOFs employing FFD</td>
<td>84</td>
</tr>
<tr>
<td>Table 3.6</td>
<td>Fractional factorial screening design matrix as per seven factor two level</td>
<td>84</td>
</tr>
<tr>
<td>Table 3.7</td>
<td>Composition of various L-SNEOFs prepared as per the experimental design</td>
<td>86</td>
</tr>
<tr>
<td>Table 3.8</td>
<td>Quality target product profile for NLCs of lopinavir</td>
<td>103</td>
</tr>
<tr>
<td>Table 3.9</td>
<td>Critical quality attributes for NLCs of lopinavir and their justifications</td>
<td>104</td>
</tr>
<tr>
<td>Table 3.10</td>
<td>Screening design as per eleven factors, two levels PBD</td>
<td>106</td>
</tr>
<tr>
<td>Table 3.11</td>
<td>Formulation and process variables with their respective high and low levels, investigated using PBD</td>
<td>106</td>
</tr>
<tr>
<td>Table 3.12</td>
<td>NLCs formulations prepared for selecting the factor levels</td>
<td>107</td>
</tr>
<tr>
<td>Table 3.13</td>
<td>Composition of various formulations prepared as per the experimental designs and translation of the coded levels employed for the optimization studies</td>
<td>109</td>
</tr>
<tr>
<td>Table 3.14</td>
<td>QTPP for self-nanoemulsifying oily formulations of darunavir</td>
<td>117</td>
</tr>
</tbody>
</table>
List of tables

Table 3.15: Critical quality attributes for self-nanoemulsifying oily formulation of darunavir and their justifications .......................................................... 118
Table 3.16: Formulation for SNEOFs with their respective low and high levels, investigated using Taguchi orthogonal array ....................................................... 120
Table 3.17: Screening design matrix as per 7-factor-2-level Taguchi ........................................ 121
Table 3.18: Composition of various SNEOFs prepared as per the experimental design ........ 122
Table 3.19: Quality target product profile for SLNs of darunavir ........................................... 127
Table 3.20: CQAs for SLNs of darunavir and their justifications ............................................. 128
Table 3.21: Formulation and process variables with their respective high and low levels investigated using FFD ........................................................................... 129
Table 3.22: Screening design matrix as per five factors, two levels FFD ............................. 129
Table 3.23: Composition of various SLN formulations prepared as per the design matrix delineating the experimental design ............................................. 131
Table 4.1: HPLC peak areas at various lopinavir concentrations for constructing the calibration plot ....................................................................................... 136
Table 4.2: Validation of accuracy for different concentrations of lopinavir ..................... 139
Table 4.3: Validation of system repeatability for lopinavir ............................................... 140
Table 4.4: Validation for intra-day and inter-day precision .............................................. 141
Table 4.5: Peak area of various concentrations of lopinavir employed for constructing the linear calibration plot ................................................................. 143
Table 4.6: Validation of accuracy for different concentrations of lopinavir ..................... 145
Table 4.7: Validation for intra-day and inter-day precision .............................................. 145
Table 4.8: Extinction coefficient values for lopinavir in various solvents ....................... 146
Table 4.9: Accuracy in measuring a known concentration of lopinavir ......................... 148
Table 4.10: Validation for intra-day and inter-day precision .......................................... 149
Table 4.11: Initial risk assessment for SNEOFs of lopinavir ............................................. 155
Table 4.12: Enlisting of wave numbers for the characteristic peaks of lopinavir .......... 158
Table 4.13: Summary of overall parameters of all the formulations prepared as per the experimental design *Formulations are prepared in duplicate .............. 163
Table 4.14: Values of polynomial and correlation coefficients for CQAs of lopinavir SNEOFs ............................................................................................................. 164
Table 4.15: Results of numeric optimization for SNEOFs of lopinavir ............................ 169
Table 4.16: Comparison of experimental responses with the predicted responses ........ 170
Table 4.17: Mathematical drug release kinetic modeling results for the OPT-L-SNEOFs .... 177
Table 4.18: Various powder properties of porous carriers employed for the preparation of L-SNEOFs tablets ............................................................................. 179
Table 4.19: Effect on the formulation parameters during the accelerated and long term stability studies ...................................................................................... 182
Table 4.20: Model fitness parameters of PK data using various weighting schemes ...... 193
Table 4.21: Pharmacokinetic parameters obtained from plasma level studies after various oral treatments .................................................................................... 196
Table 4.22: Abridged FMEA matrix enlisting the RPN scores for the selected formulation and process variables ................................................................. 202
Table 4.23: Particle size and drug entrapment efficiency of various formulations prepared to ascertain the factor levels .......................................................... 205
Table 4.24: Mean values of percent released, Ln (M_i/M_0) and rates of drug release at varied times for NLCs of lopinavir (L-NLC-1) prepared as per the BBD using blend of Compritol (300 mg), OA (100 mg), Tween 80 (6.5 g) ........................................... 211
Table 4.25: Drug release and statistical parameters for each NLC formulation ....................... 211
Table 4.26: Mean values of percent released, Ln (M_i/M_0) and rates of drug release at varied times for NLCs of lopinavir (L-NLC-8) prepared as per the BBD using blend of Compritol (300 mg), OA (150 mg), Tween 80 (6.5 g) ........................................... 212
Table 4.27: Drug release and statistical parameters for each NLC formulation ....................... 212
Table 4.28: Mean values of percent released, Ln (M_i/M_0) and rates of drug release at varied times for NLCs of lopinavir (L-NLC-11) prepared as per the BBD using blend of Compritol (300 mg), OA (125 mg), Tween 80 (5 g) ........................................... 213
Table 4.29: Drug release and statistical parameters for each NLC formulation ....................... 213
Table 4.30: Mean values of percent released, Ln (M_i/M_0) and rates of drug release at varied times for NLCs of lopinavir (L-NLC-13) prepared as per the BBD using blend of Compritol (300 mg), OA (125 mg), Tween 80 (8 g) ........................................... 214
Table 4.31: Drug release and statistical parameters for each NLC formulation ....................... 214
Table 4.32: Mean values of percent released, Ln (M_i/M_0) and rates of drug release at varied times for NLCs of lopinavir (L-NLC-2) prepared as per the BBD using blend of Compritol (450 mg), OA (150 mg), Tween 80 (5 g) ........................................... 215
Table 4.33: Drug release and statistical parameters for each NLC formulation ....................... 215
Table 4.34: Mean values of percent released, Ln (M_i/M_0) and rates of drug release at varied times for NLCs of lopinavir (L-NLC-6) prepared as per the BBD using blend of Compritol (450 mg), OA (100 mg), Tween 80 (5 g) ........................................... 216
Table 4.35: Drug release and statistical parameters for each NLC formulation ....................... 216
Table 4.36: Mean values of percent released, Ln (M_i/M_0) and rates of drug release at varied times for NLCs of lopinavir (L-NLC-3) prepared as per the BBD using blend of Compritol (450 mg), OA (125 mg), Tween 80 (6.5 g) ........................................... 217
Table 4.37: Drug release and statistical parameters for each NLC formulation ....................... 217
Table 4.38: Mean values of percent released, Ln (M_i/M_0) and rates of drug release at varied times for NLCs of lopinavir (L-NLC-4) prepared as per the BBD using blend of Compritol (450 mg), OA (150 mg), Tween 80 (8 g) ........................................... 218
Table 4.39: Drug release and statistical parameters for each NLC formulation ....................... 218
Table 4.40: Mean values of percent released, Ln (M_i/M_0) and rates of drug release at varied times for NLCs of lopinavir (L-NLC-12) prepared as per the BBD using blend of Compritol (450 mg), OA (100 mg), Tween 80 (8 g) ........................................... 219
Table 4.41: Drug release and statistical parameters for each NLC formulation ....................... 219
Table 4.42: Mean values of percent released, Ln (M_i/M_0) and rates of drug release at varied times for NLCs of lopinavir (L-NLC-9) prepared as per the BBD using blend of Compritol (600 mg), OA (100 mg), Tween 80 (6.5 g) ........................................... 220
Table 4.43: Drug release and statistical parameters for each NLC formulation ....................... 220
Table 4.44: Mean values of percent released, Ln (M_i/M_0) and rates of drug release at varied times for NLCs of lopinavir (L-NLC-5) prepared as per the BBD using blend of Compritol (600 mg), OA (125 mg), Tween 80 (5 g) ........................................... 221
Table 4.45: Drug release and statistical parameters for each NLC formulation ....................... 221
Table 4.46: Mean values of percent released, Ln (M∞/M∞) and rates of drug release at varied times for NLCs of lopinavir (L-NLC-7) prepared as per the BBD using blend of Compritol (600 mg), OA (125 mg), Tween 80 (8 g) ........................................................................................................... 222
Table 4.47: Drug release and statistical parameters for each NLC formulation.......................................................................................................................... 222
Table 4.48: Mean values of percent released, Ln (M∞/M∞) and rates of drug release at varied times for NLCs of lopinavir (L-NLC-10) prepared as per the BBD using blend of Compritol (600 mg), OA (150 mg), Tween 80 (6.5 g) ........................................................................................................... 223
Table 4.49: Drug release and statistical parameters for each NLC formulation.......................................................................................................................... 223
Table 4.50: Summary of overall drug release parameters for all NLC formulations of lopinavir prepared using different combinations of Compritol, OA and Tween 80 as per the experimental design ........................................................................................................... 224
Table 4.51: Coefficient values and statistical parameters obtained for polynomial equations for the studied CQAs .......................................................................................................................... 226
Table 4.52: Constraints and results of numeric optimization for lopinavir-loaded NLCs................................................. 235
Table 4.53: Comparison of experimental results with predicted responses .......................................................................................................................... 236
Table 4.54: Mathematical drug release kinetic modeling for the optimized NLCs.......................................................................................................................... 240
Table 4.55: Effect of storage conditions and time on various formulation parameters of lopinavir-loaded NLCs .......................................................................................................................................... 241
Table 4.56: Model fitness parameters of PK data using various weighting schemes ................................................. 247
Table 4.57: Pharmacokinetic parameters obtained from plasma level studies after various oral treatments .......................................................................................................................................... 251
Table 4.58: Statistical parameters for various mathematical models for Level A in vitro/ in vivo correlations .......................................................................................................................................... 257
Table 4.59: Statistical parameters for Level B IVIVC .......................................................................................................................... 257
Table 4.60: Statistical parameters for multiple Level C IVIVC .......................................................................................................................... 259
Table 4.61: HPLC peak areas at various darunavir concentrations for constructing the linear calibration plot .......................................................................................................................................... 262
Table 4.62: Validation of accuracy for different concentrations of darunavir .......................................................................................................................................... 264
Table 4.63: Validation of system repeatability at different darunavir concentrations ................................................. 265
Table 4.64: Validation for intra-day and inter-day precision .......................................................................................................................... 265
Table 4.65: Peak area of various concentrations of darunavir employed for constructing the linear calibration plot .......................................................................................................................................... 267
Table 4.66: Validation of accuracy for different concentrations of darunavir .......................................................................................................................................... 269
Table 4.67: Validation for intra-day and inter-day precision .......................................................................................................................... 270
Table 4.68: Extinction coefficient values for darunavir in various solvents .......................................................................................................................................... 270
Table 4.69: Accuracy in measuring a known concentration of darunavir .......................................................................................................................................... 272
Table 4.70: Validation for intra-day and inter-day precision .......................................................................................................................... 272
Table 4.71: Abridged FMEA matrix enlisting the RPN scores for the selected formulation and process variables .......................................................................................................................................... 278
Table 4.72: Values of polynomial and correlation coefficients for CQAs of darunavir SNEOFs .......................................................................................................................................... 284
Table 4.73: Results of numeric optimization for SNEOFs of darunavir .......................................................................................................................................... 289
Table 4.74: Comparison of experimental responses with the predicted responses .......................................................................................................................................... 292
Table 4.75: Mathematical drug release kinetic modeling for the OPT-D-SNEOFs .......................................................................................................................................... 295
Table 4.76: Effect of the accelerated and long term stability on the formulation parameters 303
Table 4.77: Parameters evaluated optimization of cationic SNEOFs ..................................305
Table 4.78: Model fitness parameters of PK data using various weighting schemes ......309
Table 4.79: Pharmacokinetic parameters obtained from plasma level studies after various oral treatments ........................................................................................................................................311
Table 4.80: Risk estimation matrix for initial risk assessment for SLNs of darunavir ........317
Table 4.81: Coefficient values and statistical parameters obtained for the studied response variables........................................................................................................................................318
Table 4.82: Mean values of percent released, \( \ln \left( \frac{M_t}{M_\infty} \right) \) and rates of drug release at varied times for SLNs of darunavir prepared as per experimental design using Compritol (400 mg) and Tween 80 (3 g) (D-SLN-1) ................................324
Table 4.83: Drug release and statistical parameters for each SLN formulation .................324
Table 4.84: Mean values of percent released, \( \ln \left( \frac{M_t}{M_\infty} \right) \) and rates of drug release at varied times for SLNs of darunavir prepared as per experimental design using Compritol (600 mg) and Tween 80 (3 g) (D-SLN-2) ................................325
Table 4.85: Drug release and statistical parameters for each SLN formulation .................325
Table 4.86: Mean values of percent released, \( \ln \left( \frac{M_t}{M_\infty} \right) \) and rates of drug release at varied times for SLNs of darunavir prepared as per experimental design using Compritol (400 mg) and Tween 80 (6 g) (D-SLN-3) ................................326
Table 4.87: Drug release and statistical parameters for each SLN formulation ..................326
Table 4.88: Mean values of percent released, \( \ln \left( \frac{M_t}{M_\infty} \right) \) and rates of drug release at varied times for SLNs of darunavir prepared as per experimental design using Compritol (600 mg) and Tween 80 (6 g) (D-SLN-4) ................................327
Table 4.89: Drug release and statistical parameters for each SLN formulation ..................327
Table 4.90: Mean values of percent released, \( \ln \left( \frac{M_t}{M_\infty} \right) \) and rates of drug release at varied times for SLNs of darunavir prepared as per experimental design using Compritol (500 mg) and Tween 80 (4.5 g) (D-SLN-5) ................................328
Table 4.91: Drug release and statistical parameters for each SLN formulation ..................328
Table 4.92: Mean values of percent released, \( \ln \left( \frac{M_t}{M_\infty} \right) \) and rates of drug release at varied times for SLNs of darunavir prepared as per experimental design using Compritol (400 mg) and Tween 80 (4.5 g) (D-SLN-6) ................................329
Table 4.93: Drug release and statistical parameters for each SLN formulation ..................329
Table 4.94: Mean values of percent released, \( \ln \left( \frac{M_t}{M_\infty} \right) \) and rates of drug release at varied times for SLNs of darunavir prepared as per experimental design using Compritol (600 mg) and Tween 80 (4.5 g) (D-SLN-7) ................................330
Table 4.95: Drug release and statistical parameters for each SLN formulation ..................330
Table 4.96: Mean values of percent released, \( \ln \left( \frac{M_t}{M_\infty} \right) \) and rates of drug release at varied times for SLNs of darunavir prepared as per experimental design using Compritol (500 mg) and Tween 80 (3 g) (D-SLN-8) ................................331
Table 4.97: Drug release and statistical parameters for each SLN formulation ..................331
Table 4.98: Mean values of percent released, \( \ln \left( \frac{M_t}{M_\infty} \right) \) and rates of drug release at varied times for SLNs of darunavir prepared as per experimental design using Compritol (500 mg) and Tween 80 (6 g) (D-SLN-9) ................................332
Table 4.99: Drug release and statistical parameters for each SLN formulation ..................332
Table 4.100: Summary of overall drug release parameters for all SLNs of darunavir prepared using different combinations of Compritol and Tween 80 as per the experimental design ........................................................................333
Table 4.101: Values of polynomial and correlation coefficients for CQAs of darunavir SLNs 336
Table 4.102: Feasibility search for various CQAs of darunavir-loaded SLNs...............................342
Table 4.103: Grid search for various CQAs of darunavir-loaded SLNs ........................................343
Table 4.104: Results of numeric optimization for darunavir-loaded SLNs ....................................346
Table 4.105: Comparison of experimental results with predicted responses .................................347
Table 4.106: Mathematical drug release kinetic modeling for the optimized SLNs (OPT-D-SLN) formulation........................................................................................................................................351
Table 4.107: Effect of storage conditions and time on various formulation parameters of darunavir-loaded SLNs ......................................................................................................................................352
Table 4.108: Model fitness parameters of PK data using various weighting schemes .................360
Table 4.109: Pharmacokinetic parameters obtained from plasma level studies after various oral treatments ........................................................................................................................................362
Table 4.110: Statistical parameters for various mathematical models for Level A in vitro/ in vivo correlations ............................................................................................................................................365
Table 4.111: Statistical parameters for Level B in vitro/ in vivo correlations .................................366
Table 4.112: Statistical parameters for Level C in vitro/ in vivo correlations .................................366
Table 4.108: Model fitness parameters of PK data using various weighting schemes .................369
Table 4.113: Pharmacokinetic parameters obtained from brain level studies after various oral treatments ........................................................................................................................................372